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ABSTRACT                        The discovery of the pathogenetic role of free radicals in various human and
animal diseases initiated a wide range of investigations, resulting in a number of important
scientific dicoveries. These are reviewed in this paper, with an emphasis on preventing
atherosclerotic complications and plaque development. The administration of antioxidants in
the prevention and therapy of different diseases is listed, too. The questions of optimum
antioxidant supply to prevent atherosclerosis, malignancies and other diseases are discussed.
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The discovery of free radicals (FRs) and their pathogenetic
role in the development of atherosclerosis (AS), tumours,
teratogenesis and ageing initiated a wide-ranging research on
this field (Horváth and Jávor 1985; Fehér et al. 1993; Frei
1994; Bergendy et al. 1999). This area includes the ecology
and environmental medicine and has implications in the
biological, biochemical or pharmacological investigations, as
well as in the agriculture and in the veterinary and human
medicine.
Medical and public health implications
In the “civilised” life the quantity of FRs has grown enor-
mously. Oil the main source of energy in the world, the
smoky atmosphere contains a lot of FRs generated by the
burning process (Gracy et al. 1999; Hiura et al. 1999;
Velichovszkij 2001). Xenobiotics are widely dispersed, as
well. The organochlorides have become ubiquitous. These
compounds are not only neurotoxic, but they also increase the
superoxide production in the mitochondria and cause ox-
idative damages to the DNS (Stedeford et al. 2001).
These toxic substances might be concentrated in some
foods. A sad consequence of this harmful accumulation is the
diminished fertility of eskimoes brought about by the xe-
nobiotics found in their principal nutrient, in the liver and oil
of narwals.
It is an intriguing question as to how long time can nature
compensate for this flood of FRs and which diseases or
mutations could arise.
The mass of FRs affecting the mankind has been mul-
tiplied in the last 100 years, while, in contrast, the antioxidant
(AO) intake of people has diminished. The consumption of
fresh fruits and vegetables is very low, whereas smoking,
alcohol, obesity, accompanied by a lot of faulty eating and
culinary habits increase the FR load to the human organism
(Fehér et al. 1993; Tulok and Matkovics A 1997).
The role of antioxidants in maintaining health
At the beginning of FR research a much expected possibility
was to prevent the AS and tumour development by neutraliz-
ing FR pathogenicity (Horváth and Jávor 1985). A tre-
mendous amount of scientific investigations was carried out.
More and more AO substances have become known to
provide the biomolecules an effective AO protection. Various
kinds of fruits, vegetables and medicinal plants were exam-
ined and their abundance in AO came to light (Fehér et al.
1993).
The AOs differ in their affinity to the various FRs as well
as in their binding site in the organism, e.g. vitamin E is
highly effective with the superoxide radicals but it is very
weak in scavenging hydroxyl ions. The ”master of AOs” is
vitamin E, but on the surface of biological membranes and
of the blood lipids only, whereas in the fluid spaces vitamin
C is the main AO, as glutathion acts intracellularly and
melatonin in the nerve cells. Thus: the AOs can be classified
according to their FR affinity and tissue concentrations (such
as antibiotics can). It is beyond doubt that there is neither a
generally effective AO compound, nor a universal AO treat-
ment (Matkovics A 2001). There are only some substances
scavenging certain FRs on defined cells or molecules.
When determining the AO content of a tissue or plant the
result depends on the method employed (FRAP, TAS,
TBARS, etc.). Testing different fruits in a peroxide system
plums, bananas and red grapes were the most effective
against FRs, whereas in a hypochlorite system the banana
proved to be the weakest. Similarly, examining some food
additives (butylhydroxytoluene, trinatriumpolyphosphate,
phenol, propylgallate, etc.) and spices (rosemary, red pepper
and oregano as the best ones) a different rank order was
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established in the two mentioned systems, except vitamin E,
which proved to be the weakest one (Murcia et al. 2001).
Garlic, carrots, apricots, onions, curry, citrus fruits and kale
sorts had good AO properties as well.
The advantages of tea and fish consumption are un-
doubtedly proven, but the role of red wine in preventing  AS
is still debated. The publication of the “french paradox”
prompted an intensive investigation. The results are contro-
versial, but they suggest slightly, that a moderate drinking of
red wine (1- 3 dl daily but not more!) may be protective
against AS (Goldberg et al. 2001), and, possibly, against
neoplastic diseases too. The differences of the studies on this
subject may be explained by the individual polymorphism of
alcohol metabolizing enzymes and by the different popu-
lations among which these investigations were performed.
Adverse effects of antioxidant administration
A great number of data shows that any AO can be trans-
formed to a prooxidant, especially if it is given in a high dose
and without other AOs. When being not able to step in to the
chain of electron transport the AO will be saturated and
become a FR source. Probably this is the explanation of the
failure of the „Natural” Cancer Prevention Trial (Peterson
1996). Later it was experimentally proved that high doses of
ß-carotene produce superoxide radicals.
It can, thus, be stated: ”A single antioxidant is not an
antioxidant!” (Tulok and Matkovics 1997).
A new term called ”antioxidative stress” has also been
introduced. This includes all adverse effects of AOs and the
indirect disadvantages of them. For example, the beneficial
action of exercise by the induction of aortic catalase activity
and endothelial NO synthase expression was counteracted by
the administration of vitamin E (Meilhac et al. 2001). It
means that an adaptative reaction may be hindered by the
administration of an AO. Certainly the physiological FR
reactions must not be blocked. The AOs have a Janus face!
Prevention of diseases by antioxidants
The best results of AO administration were attained in halting
the progression of AS.
The first interventional trials with the administration of
vitamin E did not yield convincing results. Although vitamin
E in chronic renal insufficiency reduced the number of
cardiovascular events by 40%, it is known, that in this
condition the atherosclerotic process quickens by up to 6 –
26% faster, than in the age-matched control people (Boaz et
al. 2000). Other studies gave minimal or negative results.
These latter ones, however,were performed on people who
probably had had AS plaques already at the beginning of the
study.
Hence it can be suggested that vitamin E really hinders
only the initial phase of AS, but has not any important
influence on the later processes of plaque development and
rupture, leading to myocardial infarction or arterial oc-
clusion, to the so- called ”hard endpoints.”
Although the early captopril studies (SAVE, SOLVD)
showed a significant reduction in stroke and cardiovasular
events, the HOPE study (The Heart Outcomes Prevention
Evaluation Study Investigators, 2000) provides the con-
vincing evidence for the effectivity of ACE inhibitors in the
impeding the AS process in the vascular wall.
Contemporary laboratory investigations have pointed out
the pathogenetic role of angiotensin-II (which is also a ROS
producer) in the process of AS: oxidizing lipoproteins,
activating macrophages and smooth muscle cells, triggering
the excretion of cytokines, adhesion – and apoptotic factors,
leading to plaque formation – thus verifying theoretically the
beneficial effects observed by the ACEi administration.
The administration of calcium channel antagonists and
the angiotensin AT1 blockers in hypertensive patients and
HMG-CoA reductases in hyperlipidemic patients provided
similar positive results to the aforementioned ones.
Corti and his co-workers measured the size of AS plaques
with a high resolution MRI method and found out that after
a year of simvastatin therapy both the diameter of AS plaques
and the thickening of the arterial wall were signif-icantly
diminished (Corti et al. 2001).
Such regression of AS plaques (in 15-18% of treated
patients) has been already observed in some studies on anti-
hyperlipidemic treatment both in the ELSA study with
lacipidin and in other statin and fibrate studies.
The atherogenetic role of hyperhomoscystinemia was
discovered in the latest years, with the hope to prevent AS
in these cases with the administration of folic acid and
vitamin B6.
The main causes of AS are summarized in Table 1.
In the prevention of neoplastic diseases no similar
achievements could have been reached. A number of studies
on successful prevention were published (Shanghai, New
Zealand, Uruguay study, etc.) but it is not clear, what kinds
of materials and in which combination and doses are nec-
essary.
The key question of cancer prevention and avoidance of
premature ageing seems to be the AO protection of the DNS
and the mitochondria (Van Remmer and Richardson 2001;
László and Falus 2002). An immense research is going on for
newer and better mitochondrial and DNS-protecting AO
substances.
Antioxidants in the therapy
Every illness or tissue damage leads to an increased FR gen-
eration and these radicals cause further injuries (Matkovics
1993). Therefore each disease leads to a common, unspecific
complication: the oxidative stress. So: the administration of
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AOs is reasonable in all diseases, in the form of the poly-AO
therapy. The results of this approach have already been
published in a lot of articles. In cases of polytraumatized
patients (Porter et al. 1999) burns and in other critically
serious conditions a higher percentage of recovery was
observed during the AO treatment (N-acetylcysteine,
selenium, Vitamin C+E, allopurinol and lazaroid
combination): with a smaller rate of infections, cardiovas-
cular or other complications (Bulger and Maier 2001). In
subarachnoidal hemorrhages a smaller percent of brain
damages was found in the AO group than in the control ones
(Asano and Matsui 1999). Similarly, Goode (1993) observed
hopeful outcomes in sepsis cases by the combined AO
administration.
Professor Boda had been investigating the uric acid
metabolism since the 60’s and based on his own results he
saved the life of many children with serious conditions (such
as shock, or respiratory distress syndrome) by the allopurinol
treatment (Boda and Németh 1983). It came to light only
later, that in such clinical states the xanthine oxidase activity
has increased, resulting in a high overproduction of super-
oxide radicals.
In the course of the influenza the ROS derived from the
macrophages causes more damages than the influenza virus
itself (Jacoby 1994). Hemila and Douglas (1999) pointed out,
that vitamin C is really effective in acute respiratory in-
fections, but it must be given in high doses, such as 2000 mg
daily.
The combinations of AO compounds (mostly based on
silymarin with other AOs) has proved to be effective in the
therapy of different (toxic and infective) hepatic diseases
(Berkson 1990; Fehér and Vereckei 1990; Fehér 2002). Good
effect was observed with a vitamin C, coenzyme Q10, ß-
carotene combination in primary biliary cirrhosis (Watson et
Table 1.  Factors of atherogenesis.
Cause  Pathomechanism
Hypertension  Endothel  dysfunction and lesion
 Biomechanical (shear) stress
 Overproduction of endothelin and angiotensin
Hyperlipidemias  Oxidised  LDL
 Lipoprotein-A ; remnant- lipoproteins
Hypercholesterinemia  Triglyceride and free fatty acids
Dyslipidemia  Leptin
Obesity  Deficiency in HDL
Metabolic X syndrome
Hyperfibrinogenemia  Enhanced activity of thrombocyte mitogenes   and
Hypercoagulation syndromes  LDL binding capacity of the vascular wall
 ncreased smooth cell proliferation and migration.
Smoking  Increased lipid peroxidation
 Oxidative stress in the vascular wall
 Vasoconstriction,  ischaemia , generation  of  ROS
Hyperhomocysteinemia
a) congenital, (b) deficiency in vitamine B
6   
and  Autooxidation  products of ROS  (peroxide and
      c) folic acid  superoxide radicals)
d.)  Diabetes mellitus type 2.  (NIDDM)  Inhibition of glutathion peroxidase
Generalized oxidative stress                                                                               Increased lipid peroxidation
Critically severe conditions:burns, polytraumatization,  Endothelial damage caused by ROS
respiratory distress syndrome, serious infection, etc.)
Nutritional AO deficiencies, alcoholism,  Weakness in defense to ROS
Abundant lipid intake (including PUFA )  Oxidative stress
 Increased lipid peroxidation
Ageing  Increased production of mitochondrial ROS.  Oxidation
 of membrane lipids Lipid peroxidation enhanced.
Diabetes mellitus  (mainly Type 2)  Glycation products, glycotoxicity, lipotoxicity
Chronic renal insufficiency  A general increase in ROS production
 Enhanced lipid peroxidation
Infections, inflammations, autoimmune diseases (SLE)  Increased inflammatory reactions in the vascular wall
(Chlamydia, CMV, herpes viruses, oral pathogenes, focal infections, etc.)
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al. 1999). The chronic pancreatitis was influenced favour-
ably with selenium compounds (Bowrey et al. 1992).
A vast body of literature testifies that a row of renal
(Annuk et al. 2001; Clermont et al. 2001), hematological
(Németh et al. 2000), autoimmune, gynaecologic, neurologic
and metabolic disorders have been influenced favourably by
the AO treatment, as summarized by Matkovics (2001).
There is a large quantity of materials which are effective
against experimental carcinogenesis or they cause apoptosis
of tumour cells – but not in curing human malignancies. In
the malignant cell lines the pycnogenol, allicin and resver-
atrol showed the greatest antitumour activity. The clinical
results have been scarce until now. Lockwood et al. (1994)
published surprisingly good effects with a megadose coen-
zyme Q10 and multivitamin therapy, but these are still not
confirmed by other investigators.
In clinical oncology the AOs have at present a rather
adjuvant role, e.g. glutathion alleviates the toxic side effects
of cysplatin therapy.
Some open questions
According to our present knowledge, the most important
questions are still to be answered, e.g.: What does the optimal
AO supply consist of? How many AOs must be taken and in
what dosage? How can we provide a safe AO protection for
the most important biomolecules without any harmful effect?
Nowadays the wisest advice might be: taking as many
kinds of natural AO-s as it is possible, and in proportions
resembling natural foods.
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